Just to add to your post BDAZ, we should all remember that in ASSURE, wrt plaque reduction, had the distinction between Apabetalone + rosuvastatin vs Apabetalone + atorvastatin been a pre-specified end point ASSURE would have been a big success. It would seem that the RVX team is not about to make the same mistake twice.